Immune activation in the small intestine in patients with rheumatoid arthritis

Objectives: To determine whether inflammation in the gut associated immune system is activated in rheumatoid arthritis (RA). The expression of chemokine receptor- (CCR4, CCR5) and cytokine- (interleukin (IL)2, IL10, interferon γ (IFNγ), tumour necrosis factor α (TNFα), and transforming growth factor...

Full description

Saved in:
Bibliographic Details
Published inAnnals of the rheumatic diseases Vol. 63; no. 10; pp. 1327 - 1330
Main Authors Nissinen, R, Leirisalo-Repo, M, Nieminen, A M, Halme, L, Färkkilä, M, Palosuo, T, Vaarala, O
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group Ltd and European League Against Rheumatism 01.10.2004
BMJ
Elsevier Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objectives: To determine whether inflammation in the gut associated immune system is activated in rheumatoid arthritis (RA). The expression of chemokine receptor- (CCR4, CCR5) and cytokine- (interleukin (IL)2, IL10, interferon γ (IFNγ), tumour necrosis factor α (TNFα), and transforming growth factor β (TGFβ)) specific mRNA in intestinal biopsy samples from patients with RA was examined. Methods: Duodenal biopsy samples from 13 patients with RA and 15 control subjects were studied. The mRNA expression of CCR4, CCR5, IL2, IL10, IFNγ, TNFα, and TGFβ in intestinal biopsy samples was demonstrated by real time quantitative reverse transcriptase-polymerase chain reaction. Results: The mRNA expression of CCR4, CCR5, and IL10 in intestinal biopsy samples was increased in patients with RA in comparison with control subjects (p = 0.001, p = 0.046, p = 0.019). No difference in the expression levels of IL2, IFNγ, TNFα, or TGFβ was seen between patients with RA and controls. Conclusions: The increased intestinal mRNA expression of IL10, CCR5, and CCR4 suggests that gut associated immune cells are activated in patients with RA.
Bibliography:PMID:15361394
href:annrheumdis-63-1327.pdf
istex:01CF8837116F65478CFB0F36D4D5232C680EC9C7
local:0631327
Correspondence to:
 Dr R Nissinen
 National Public Health Institute, Department of Molecular Medicine, Biomedicum, PO Box 104, 00251 Helsinki, Finland; riikka.nissinen@ktl.fi
ark:/67375/NVC-L1HHDPZJ-0
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:0003-4967
1468-2060
1468-2060
DOI:10.1136/ard.2003.011304